公开(公告)号：US10238631B2

公开(公告)日：2019-03-26

申请号：US15316700

申请日：2015-06-05

Applicant: Academia Sinica

Inventor： Lie-Fen Shyur ,  Kuo-Hsiung Lee ,  Kyoko Nakagawa-Goto ,  Jia-Hua Feng ,  Jo-Yu Chen ,  Wai-Leng Lee ,  Yu-Ting Cheng ,  Jing-Ying Huang

IPC: A61K31/365 ,  A61K45/06 ,  A61K31/337 ,  A61K31/437 ,  C07D493/18 ,  A61K31/198 ,  A61K31/655

Abstract: A new class of sesquiterpene derivative useful for treating cancerous and inflammatory diseases are disclosed. These deoxyelephantopin derivatives are effective in suppressing proliferation, migration, mobility, invasion, growth, and/or metastasis of cancer cells in a patient, or useful for enhancing an anti-proliferative effect of another anti-cancer drug on cancer cells when treating a patient, or for sensitizing and/or enhancing an anti-cancer effect of a gluthathione synthesis blocker on inhibition of triple negative breast cancer cell activity, or for treatment and/or prophylaxis of lipopolysaccharide-stimulated inflammatory response in a patient, or for all of the above. Also disclosed are methods of preparing the deoxyelephantopin derivatives.

公开(公告)号：US08728787B2

公开(公告)日：2014-05-20

申请号：US13923816

申请日：2013-06-21

Applicant: Academia Sinica

Inventor： Lie-Fen Shyur

IPC: C12N9/02 ,  C12Q1/26 ,  C07K14/00 ,  C12P21/00

CPC classification number: C12N9/0061 ,  C12Y110/03002

Abstract: Novel laccases from Cerrena sp. WR1 and Lentinus sp. and uses thereof.

Abstract translation: Cerrena sp。的新型漆酶 WR1和香菇属 及其用途。

公开(公告)号：US20130273631A1

公开(公告)日：2013-10-17

申请号：US13923816

申请日：2013-06-21

Applicant: Academia Sinica

Inventor： Lie-Fen Shyur ,  Chih-An Hsu

IPC: C12N9/00

CPC classification number: C12N9/0061 ,  C12Y110/03002

Abstract: Novel laccases from Cerrena sp. WR1 and Lentinus sp. and uses thereof.

Abstract translation: Cerrena sp。的新型漆酶 WR1和香菇属 及其用途。

公开(公告)号：US09493751B2

公开(公告)日：2016-11-15

申请号：US14212231

申请日：2014-03-14

Applicant: Academia Sinica

Inventor： Lie-Fen Shyur ,  Wei-Chun Liu

IPC: C12N9/24

CPC classification number: C12N9/2405

Abstract: Described herein is a fusion polypeptide that contains (a) a first segment containing a Fibrobacter succinogenes 1,3-1,4-β-D-glucanase (Fsβ-glucanase) or a fragment thereof; (b) a second segment containing a first Thermotoga maritima 1,3-β-D-glucanase (TmLam) or a fragment thereof; and (c) an optional third segment containing a second Thermotoga maritima 1,3-β-D-glucanase (TmLam) or a fragment thereof; wherein the fusion polypeptide has a glucanase activity. Also described are a nucleic acid molecule encoding the fusion polypeptide and a method of using the polypeptide.

Abstract translation: 本文描述的是融合多肽，其包含（a）含有富含纤维杆菌的纤维杆菌1,3-1,4-β-D-葡聚糖酶（Fsβ-葡聚糖酶）或其片段的第一片段; （b）含有第一热转录生物海参1,3-β-D-葡聚糖酶（TmLam）或其片段的第二片段; 和（c）任选的第三片段，其含有第二种海绵假单胞菌1,3-β-D-葡聚糖酶（TmLam）或其片段; 其中所述融合多肽具有葡聚糖酶活性。 还描述了编码融合多肽的核酸分子和使用该多肽的方法。

公开(公告)号：US09173868B2

公开(公告)日：2015-11-03

申请号：US14269043

申请日：2014-05-02

Applicant: Academia Sinica

Inventor： Lie-Fen Shyur ,  Wen-Wan Chao ,  Ya-Wen Cheng

IPC: A61K31/365 ,  A61K33/24 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/436 ,  A61K31/44 ,  A61K31/454 ,  A61K31/475 ,  A61K31/506 ,  A61K31/56 ,  A61K31/655 ,  A61K31/69 ,  A61K31/704 ,  A61K36/28 ,  A61K45/06

CPC classification number: A61K31/365 ,  A61K31/415 ,  A61K31/4188 ,  A61K31/436 ,  A61K31/44 ,  A61K31/454 ,  A61K31/475 ,  A61K31/506 ,  A61K31/56 ,  A61K31/655 ,  A61K31/69 ,  A61K31/704 ,  A61K33/24 ,  A61K36/28 ,  A61K45/06

Abstract: Methods for preventing and/or reducing side effects of an anti-cancer agent in a subject in need thereof are disclosed. The method comprises administering to the subject, who is under an anti-cancer agent treatment, a composition comprising a therapeutically effective amount of isolated deoxyelephantopin and/or an analog thereof; and a pharmaceutically acceptable carrier.

Abstract translation: 公开了在有需要的受试者中预防和/或减少抗癌剂的副作用的方法。 该方法包括对患有抗癌药物治疗的受试者施用包含治疗有效量的分离的脱氧耳环素和/或其类似物的组合物; 和药学上可接受的载体。

公开(公告)号：US20140273154A1

公开(公告)日：2014-09-18

申请号：US14212231

申请日：2014-03-14

Applicant: Academia Sinica

Inventor： Lie-Fen Shyur ,  Wei-Chun Liu

IPC: C12N9/24

CPC classification number: C12N9/2405

Abstract: Described herein is a fusion polypeptide that contains (a) a first segment containing a Fibrobacter succinogenes 1,3-1,4-β-D-glucanase (Fsβ-glucanase) or a fragment thereof; (b) a second segment containing a first Thermotoga maritima 1,3-β-D-glucanase (TmLam) or a fragment thereof; and (c) an optional third segment containing a second Thermotoga maritima 1,3-β-D-glucanase (TmLam) or a fragment thereof; wherein the fusion polypeptide has a glucanase activity. Also described are a nucleic acid molecule encoding the fusion polypeptide and a method of using the polypeptide.

Abstract translation: 本文描述的是融合多肽，其包含（a）含有富含纤维杆菌的纤维杆菌1,3-1,4-葡聚糖酶（Fs＆bgr-D-葡聚糖酶）或其片段的第一片段; （b）含有第一海马体细胞1,3-葡聚糖酶（TmLam）或其片段的第二片段; 和（c）任选的第三片段，其中含有第二种海绵马来酸1,3-葡聚糖酶（TmLam）或其片段; 其中所述融合多肽具有葡聚糖酶活性。 还描述了编码融合多肽的核酸分子和使用该多肽的方法。

公开(公告)号：US11872260B2

公开(公告)日：2024-01-16

申请号：US16585984

申请日：2019-09-27

Applicant: ACADEMIA SINICA

Inventor： Lie-Fen Shyur ,  Chih-Ting Chang ,  Yuhsin Chen

IPC: A61K36/534 ,  A61K31/015 ,  A61P35/00 ,  A61K31/122 ,  A61K9/00

CPC classification number: A61K36/534 ,  A61K31/015 ,  A61K31/122 ,  A61P35/00 ,  A61K9/0014

Abstract: This disclosure is directed to essential oils, and methods of their use in treating skin conditions. The skin conditions include those involving HRASQ61L mutant keratinocyte activity, wherein the essential oil inhibits said activity to treat and/or prevent skin cancer. Particularly, the present invention denotes to and composition for inhibiting and prevent skin carcinogenesis or BRAF inhibitor, a type of anti-cancer drug induced cutaneous side effect.

公开(公告)号：US11517600B2

公开(公告)日：2022-12-06

申请号：US16963992

申请日：2018-05-29

Applicant: ACADEMIA SINICA

Inventor： Lie-Fen Shyur ,  Maria Karmella Apaya ,  Meng-Ting Chang

IPC: A61P35/04 ,  A61K36/28 ,  A61K31/045 ,  A61K31/7032 ,  A61K31/704

Abstract: A method for treating breast cancer and/or treating breast cancer metastasis in a subject in need of such treatment including administering to said subject an effective amount of Crassocephalum rabens extract and optionally a pharmaceutically acceptable carrier or excipient.

公开(公告)号：US10434132B2

公开(公告)日：2019-10-08

申请号：US16172428

申请日：2018-10-26

Applicant: ACADEMIA SINICA

Inventor： Lie-Fen Shyur ,  Jia-Hua Feng ,  Maria Karmella Apaya

IPC: A61K36/00 ,  A61K36/88 ,  A61K31/25 ,  A61K36/28 ,  A61K8/9794 ,  A61Q19/02 ,  A61P1/16 ,  A61P31/04

Abstract: The present invention is related to a galactolipids-enriched plant extract, prepared by extracting a plant sample selected from a group consisting of: Gynura divaricata subsp. formosana (Asteraceae) (GD), Murdannia bracteata (C. B. Clarke) J. K. Morton ex D. Y. Hong (Commelinaceae) (MB), and Crassocephalum rabens S. Moore (Asteraceae) (CR) with a series of solvents. A pharmaceutical, nutritional, or healthcare composition for protecting or treating acute fulminant hepatitis, for protecting or treating sepsis or related indication thereof, and a composition for skin whitening are also provided herein. These compositions all comprise effective amounts of the galactolipids-enriched plant extracts or purified compounds thereof as bioactive ingredients.